{"mainPropery":{"diseaseId":2714,"diseaseName":"Hodgkin lymphoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/2714/hodgkin-lymphoma","synonyms":["Hodgkin disease","Hodgkin's lymphoma","Lymphoma, Hodgkin's"],"synonyms-with-source":[{"name":"Hodgkin disease"},{"name":"Hodgkin's lymphoma"},{"name":"Lymphoma, Hodgkin's"}],"identifiers":[{"identifierType":"OMIM","identifierId":"236000"},{"identifierType":"ORPHANET","identifierId":"98293"},{"identifierType":"UMLS","identifierId":"C0019829"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[{"resourceID":551,"resourceName":"Lymphoma Research Foundation","abbreviation":"","address1":"Wall Street Plaza","address2":"88 Pine Street, Suite 2400","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10005","country":"United States","phone":"+1-212-349-2910","tty":"","tollFree":"1-800-500-9976","fax":"+1-212-349-2886","email":"helpline@lymphoma.org","url":"https://www.lymphoma.org/","freeText":""},{"resourceID":570,"resourceName":"Leukemia and Lymphoma Society","abbreviation":"","address1":"3 International Drive, Suite 200","address2":"","address3":"","address4":"","address5":"","city":"Rye Brook","state":"NY","zip":"10573","country":"United States","phone":"1-(888) 557-7177 (general)","tty":"","tollFree":"1-(800) 955-4572 (patients and families)","fax":"","email":"https://www.lls.org/content/contact-us","url":"https://www.lls.org/","freeText":""},{"resourceID":4088,"resourceName":"Lymphoma Coalition","abbreviation":"","address1":"8 Stavebank Road N, Unit #401","address2":"","address3":"","address4":"","address5":"","city":"Mississauga, Ontario","state":"","zip":"L5G 2T4","country":"Canada","phone":"","tty":"","tollFree":"","fax":"","email":"https://www.lymphomacoalition.org/contact/contact-us","url":"https://lymphomacoalition.org","freeText":""},{"resourceID":4089,"resourceName":"Lymphoma Action","abbreviation":"","address1":"3 Cromwell Court","address2":"New Street ","address3":"","address4":"","address5":"","city":"Aylesbury","state":"","zip":"HP20 2PB","country":"United Kingdom","phone":"0808 808 5555","tty":"","tollFree":"0808-808-5555","fax":"","email":"information@lymphoma-action.org.uk","url":"https://lymphoma-action.org.uk","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/236000' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=236000' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Hodgkin lymphoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Hodgkin+lymphoma%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Hodgkin lymphoma. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0019829' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://www.rarediseases.org/rare-disease-information/rare-diseases/byID/662/viewAbstract' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1529,"resourceId":2128,"resourceName":"MedlinePlus","descriptionText":"<a href='http://www.nlm.nih.gov/medlineplus/ency/article/000580.htm' target='_blank'>MedlinePlus</a> was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.\r\n<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=98293' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1543,"resourceId":2171,"resourceName":"National Cancer Institute","descriptionText":"The <a href='http://www.cancer.gov/cancertopics/types/hodgkin' target='_blank'>National Cancer Institute</a> provides the most current information on cancer for patients, health professionals, and the general public.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1545,"resourceId":2173,"resourceName":"Merck Manual","descriptionText":"The <a href='http://www.merck.com/mmpe/sec11/ch143/ch143b.html#sec11-ch143-ch143b-849' target='_blank'>Merck Manuals Online Medical Library</a> provides information on this condition for patients and caregivers.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:8567' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":11955,"relatedDiseaseName":"Lymphoma","relation":"Parent","isRare":false,"hasGardPage":false}],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":13704,"phenoTypeName":"Fatigue","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10673,"phenoTypeName":"Immunodeficiency","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13313,"phenoTypeName":"Lymphadenopathy","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13815,"phenoTypeName":"Lymphoma","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13430,"phenoTypeName":"Anorexia","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11831,"phenoTypeName":"Chest pain","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":9070,"phenoTypeName":"Cough","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":13043,"phenoTypeName":"Fever","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8263,"phenoTypeName":"Hyperhidrosis","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8271,"phenoTypeName":"Pruritus","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":5059,"phenoTypeName":"Weight loss","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":8720,"phenoTypeName":"Ataxia","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13280,"phenoTypeName":"Bone pain","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13726,"phenoTypeName":"Dyspnea","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":11409,"phenoTypeName":"Headache","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":13737,"phenoTypeName":"Hemoptysis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":8115,"phenoTypeName":"Hepatomegaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":2230,"phenoTypeName":"Peripheral neuropathy","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":3886,"phenoTypeName":"Splenomegaly","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":4891,"phenoTypeName":"Hodgkin lymphoma","percentRanges":"-"},{"phenoTypeId":3993,"phenoTypeName":"Impaired lymphocyte transformation with phytohemagglutinin","percentRanges":"-"},{"phenoTypeId":13577,"phenoTypeName":"Polyclonal elevation of IgM","percentRanges":"-"}],"medicalProducts":[{"productId":537,"genericName":"Brentuximab vedotin","tradeName":"Adcetris","tradeLink":"https://adcetris.com/","manufacturer":"","sponsor":"Seattle Genetics, Inc","indication":"March 2018, brentuximab vedotin (Adcetris) was approved for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.  In August 2015, it was approved for treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT).  In August 2011, it was approved for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/adcetris","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a611052.html"},{"productId":669,"genericName":"Pembrolizumab","tradeName":"Keytruda","tradeLink":"https://www.keytruda.com/classical-hodgkin-lymphoma/","manufacturer":"","sponsor":"Merck Sharp & Dohme Corp","indication":"Treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior lines of therapy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/keytruda","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a614048.html"},{"productId":647,"genericName":"Nivolumab","tradeName":"Opdivo","tradeLink":"https://www.opdivo.com/relapsed-or-progressed-chl","manufacturer":"","sponsor":"Bristol-Myers Squibb Co","indication":"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/opdivo","medlinePlusLink":"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a614056.html"}],"EncodedName":"Hodgkin_lymphoma"}